Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and Females ≥18 years.~2. Cognitive competitiveness.~3. Diagnosis of at least moderate COPD (postbronchodilator FEV1/FVC \< 70% (\<0.7), FEV1 \< 80% predicted).~4. Diffusing capacity impairment (DLCO) assessed by single breath test (corrected for alveolar volume, 'DLVA').~5. Life expectancy greater than 12 months.~6. Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf.~7. Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits.~8. No changes in active pulmonary medications for heart failure during the two weeks prior enrollment.~10. Written informed consent. 11. Non-smoker or Past smoker, with 20 pack-years or more history~Exclusion Criteria:~1. Current smokers.~2. Unstable coronary disease.~3. Patients with industrial exposure to silica and/or asbestos or giant bullae.~4. Uncontrolled seizure disorder.~5. Dementia.~6. Presence of immune deficiency or autoimmune disease.~7. Alpha- 1 antitrypsin deficiency.~8. Cor pulmonale or diastolic heart failure NYHA class III or IV~9. Type 1 diabetes mellitus~10. Complicated type 2 diabetes mellitus.~11. Active tuberculosis or severe lung damage due to tuberculosis (extensive cavitation).~12. History of cancer within the past 5 years.~13. Clinically-significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests.~14. Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.~15. Porphyria.~16. Allergy to sodium citrate or any caine type of local anesthetic.~17. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as patients undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADSCs administration (Type: EXPERIMENTAL): Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).